1 / 25

TOC - Global MRD Testing Market (2021-2027)

The minimal residual disease (MRD) testing market is projected to reach $2,611.2 million by 2027 from $1,089.3 million in 2021, at a CAGR of 14.53%. The market is driven by certain factors, such as the rising incidence of hematologic malignancies, increasing consumer awareness for tailored therapy, increasing research funding from the National Cancer Institute and increasing disposable income in emerging economies.

bisreports
Download Presentation

TOC - Global MRD Testing Market (2021-2027)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. res MRD Testing Market- A Global and Country Analysis Table of Content Focus on Technology, Application, End User, Region Global MRD Testing Market Analysis and Forecast 2022-2027 June 2022 1 All rights reserved at BIS Research Inc.

  2. BIS Research is a leading market intelligence and technology research company. BIS Research publishes in- depth market intelligence reports focusing on the market estimations, technology analysis, emerging high- growth applications, deeply segmented granular country-level market data and other important market parameters useful in the strategic decision making for senior management. BIS Research provides multi-client reports, company profiles, databases, and custom research services. Copyright © 2022 BIS Research Inc. Global MRD Testing Market All Rights Reserved. This document contains highly confidential information and is the sole property of BIS Research. Disclosing, copying, circulating, quoting, or otherwise reproducing any or all contents of this document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people or organization concerned. It may not be accessed by or offered whether for sale or otherwise to any third party. 2 All rights reserved at BIS Research Inc.

  3. Table of Content Executive Summary .......................................................................... 25 1.Market ....................................................................................... 33 1.1 Product Definition and Market Scope ............................................................ 34 1.2 Inclusion and Exclusion .................................................................................. 34 1.3 Scope of Work .................................................................................................. 34 1.4 Key Questions Answered in the Report......................................................... 35 2.Research Methodology .............................................................. 37 2.1 Global MRD Testing Market: Research Methodology ................................... 37 2.2 Primary Data Sources ..................................................................................... 37 2.3 Secondary Data Sources ................................................................................ 38 2.4 Market Estimation Model ................................................................................. 39 2.5 Criteria for Company Profiling ........................................................................ 41 3.Market Overview ........................................................................ 43 3.1 MRD Testing: Introduction .............................................................................. 43 3.2 MRD Testing: Solid Tumor vs. Hematological Malignancy .......................... 44 3.3 Market Footprint .............................................................................................. 44 Market Size and Future Growth Potential ...................................................... 45 4.Market Dynamics ....................................................................... 47 3.4 4.1 Impact Analysis ............................................................................................... 48 4.2 Market Drivers .................................................................................................. 49 4.2.1Rising Incidence of Hematological Malignancies ..................................... 49 4.2.2Increasing Consumer Awareness for Tailored Therapy .......................... 52 4.2.3Increase in Research Funding from National Cancer Institute ............... 53 4.2.4Increasing Disposable Income in Emerging Economies ......................... 53 Global MRD Testing Market 4.3 Market Restraints ............................................................................................. 54 4.3.1False Negatives and Positives ................................................................... 54 4.3.2Uncertain Reimbursement and Regulatory Policies ................................ 55 4.3.3Lack of Trained Professionals ................................................................... 55 3 All rights reserved at BIS Research Inc.

  4. 4.3.4Lack of Established Treatment Protocols for High-Value Tests in Emerging Economies .................................................................................. 56 4.4 Market Opportunities ....................................................................................... 56 4.4.1Potential Long-Term Cost Savings ............................................................ 56 4.4.2Increasing Market Access in Emerging Economies ................................. 56 4.4.3Technological Evolution of Testing ........................................................... 57 4.4.3.1 10- and 12-Color Flow Cytometry ...................................................................... 57 4.4.3.2 PCR for Gene Rearrangements ........................................................................ 57 4.4.3.3 NGS and Multiplexing ........................................................................................ 58 5.Industry Insights ........................................................................ 59 5.1 Approval Scenario ........................................................................................... 60 5.1.1Approved Minimal Residual Disease Tests by Major Players ................. 60 5.1.2Launched Minimal Residual Disease Tests (by Major Players) ............... 60 5.2 Financing Scenario .......................................................................................... 61 5.2.1Key Players’ Stratification (as Per Raised Financing Value) ................... 61 5.2.2Key Players’ Financing Analysis (FY2019-2021)....................................... 61 5.3 Regulatory Framework .................................................................................... 61 5.3.1Legal Requirements and Framework in the U.S. ...................................... 61 5.3.2Legal Requirements and Framework in Europe ....................................... 63 5.3.3Legal Requirements and Framework in Asia-Pacific ............................... 66 5.3.3.1 Japan ................................................................................................................. 66 5.3.3.2 China ................................................................................................................. 67 5.3.3.3 India ................................................................................................................... 68 5.4 Reimbursement Scenario ................................................................................ 70 5.4.1North America .............................................................................................. 70 Global MRD Testing Market 5.4.1.1 Outpatient Department (OPD) vs. Inpatient Department (IPD) .......................... 72 5.4.2European Union ........................................................................................... 73 5.4.2.1 OPD vs. IPD ...................................................................................................... 74 5.4.3Asia-Pacific .................................................................................................. 74 5.5 Supply Chain Analysis .................................................................................... 75 4 All rights reserved at BIS Research Inc.

  5. 5.5.1For Laboratory Developed Tests (LDTs) ................................................... 75 5.5.2For In-Vitro Diagnostics (IVDs)................................................................... 75 5.6 Price Sensitivity Analysis (Elasticity) ............................................................ 76 5.6.1Physicians’ Perception ............................................................................... 76 5.6.1.1 Turnaround Time (TAT) ..................................................................................... 76 5.6.1.2 Test Sensitivity ................................................................................................... 76 5.6.2Investors’ Perception .................................................................................. 77 5.6.2.1 Turnaround Time (TAT) ..................................................................................... 77 5.6.2.2 Test Sensitivity ................................................................................................... 77 5.6.3Payors’ Perception ...................................................................................... 77 5.6.3.1 Turnaround Time (TAT) ..................................................................................... 77 5.6.3.2 Test Sensitivity ................................................................................................... 78 6.Global Minimal Residual Disease Testing Market: Competitive Insights ..................................................................................... 79 6.1 Overview ........................................................................................................... 80 6.2 Synergistic Activities ...................................................................................... 81 6.3 Product Approvals ........................................................................................... 82 6.4 Product Launches and Updates ..................................................................... 83 6.5 Merger and Acquisition Activities .................................................................. 84 6.6 Business Expansion and Funding Activities ................................................ 85 6.7 Other Developments ........................................................................................ 86 6.8 Market Share Analysis, 2020-2021 ................................................................. 86 6.9 Growth-Share Analysis ................................................................................... 87 6.9.1Growth-Share Analysis (by Company) ...................................................... 87 6.9.2Growth-Share Analysis (by Technology) .................................................. 89 Global MRD Testing Market 6.9.3Growth-Share Analysis (by Application) ................................................... 90 6.9.4Growth-Share Analysis (by End User) ....................................................... 91 7.Global Minimal Residual Disease Testing Market: Stakeholder Analysis (N=30-40) ..................................................................... 92 7.1 Physicians’ Perception ................................................................................... 93 5 All rights reserved at BIS Research Inc.

  6. 7.1.1Stage of the Treatment Use for MRD ......................................................... 93 7.1.2Frequency of Receiving MRD Testing ....................................................... 93 7.1.3Average Treatment Duration for Patients Diagnosed with MRD ............. 94 7.1.4Adoption and Barriers to MRD Testing ..................................................... 95 7.2 Payors’ Perception .......................................................................................... 96 7.2.1Reimbursement vs. Patient Out-of-Pocket Expense ................................ 96 7.3 Investors’ Perception ...................................................................................... 96 7.3.1Price vs. Sensitivity vs. Turnaround time ................................................. 96 8.Global Minimal Residual Testing Market (by Technology), 2021-2027 .................................................................................. 98 8.1 Overview ........................................................................................................... 99 8.2 Flow Cytometry .............................................................................................. 100 8.3 Polymerase Chain Reaction (PCR) ............................................................... 102 8.4 Next-Generation Sequencing (NGS) ............................................................ 104 Other Technologies ....................................................................................... 106 9.Global Minimal Residual Testing Market (by Application), 2021-2027 ................................................................................ 108 8.5 9.1 Overview ......................................................................................................... 109 9.2 Hematological Malignancy ............................................................................ 111 9.2.1Non-Hodgkin’s Lymphoma (NHL) ............................................................ 112 9.2.1.1 Non-Hodgkin’s Lymphoma (NHL) (by Type) .................................................... 113 9.2.1.2 Non-Hodgkin’s Lymphoma (NHL) (by Age) ..................................................... 114 9.2.2Multiple Myeloma (MM) ............................................................................. 114 9.2.2.1 Multiple Myeloma (MM) (by Age) ..................................................................... 115 9.2.3Acute Lymphoblastic Leukemia (ALL) .................................................... 116 Global MRD Testing Market 9.2.3.1 Acute Lymphoblastic Leukemia (ALL) (by Age) ............................................... 117 9.2.4Chronic Lymphocytic Leukemia (CLL) .................................................... 117 9.2.4.1 Chronic Lymphocytic Leukemia (CLL) (by Age) .............................................. 119 9.2.5Acute Myeloid Leukemia (AML)................................................................ 119 9.2.5.1 Acute Myeloid Leukemia (AML) (by Age) ........................................................ 120 6 All rights reserved at BIS Research Inc.

  7. 9.2.6Chronic Myeloid Leukemia (CML) ............................................................ 121 9.2.6.1 Chronic Myeloid Leukemia (CML) (by Age) ..................................................... 122 9.2.7Hodgkin’s Lymphoma (HL) ....................................................................... 122 9.2.7.1 Hodgkin’s Lymphoma (HL) (by Age) ................................................................ 123 9.2.8Other Leukemia ......................................................................................... 124 10.Global Minimal Residual Disease Testing Market (by End User), 2021-2027 ..................................................................... 125 10.1Overview ......................................................................................................... 126 10.2Hospitals and Specialty Clinics .................................................................... 126 10.2.1Hospitals and Specialty Clinics (by Technology) ................................... 128 10.3Diagnostic Laboratories ................................................................................ 129 10.3.1Diagnostic Laboratories (by Technology) ............................................... 131 10.4Research Institutions .................................................................................... 132 10.4.1Research Institutions (by Technology) ................................................... 134 10.5Other End Users ............................................................................................ 135 10.5.1Other End Users (by Technology) ............................................................ 137 11.Global Minimal Residual Disease Testing Market (by Region), 2021-2027 ................................................................................ 139 11.1Overview ......................................................................................................... 140 11.2North America ................................................................................................ 141 11.2.1U.S. ............................................................................................................. 143 11.2.1.1 U.S. Minimal Residual Disease Testing Market (by Application) ..................... 144 11.2.2Canada ....................................................................................................... 147 11.2.2.1 Canada Minimal Residual Disease Testing Market (by Application) ............... 147 11.3Europe ............................................................................................................ 149 Global MRD Testing Market 11.3.1Germany ..................................................................................................... 152 11.3.1.1 Germany Minimal Residual Disease Testing Market (by Application) ............. 153 11.3.2Italy ............................................................................................................. 155 11.3.2.1 Italy Minimal Residual Disease Testing Market (by Application) ..................... 155 11.3.3France ......................................................................................................... 158 7 All rights reserved at BIS Research Inc.

  8. 11.3.3.1 France Minimal Residual Disease Testing Market (by Application) ................. 159 11.3.4U.K. ............................................................................................................. 161 11.3.4.1 U.K. Minimal Residual Disease Testing Market (by Application) ..................... 162 11.3.5Spain ........................................................................................................... 163 11.3.5.1 Spain Minimal Residual Disease Testing Market (by Application) ................... 164 11.3.6Rest-of-Europe........................................................................................... 166 11.3.6.1 Rest-of-Europe Minimal Residual Disease Testing Market (by Application) ......................................................................................................................... 168 11.4Asia-Pacific .................................................................................................... 170 11.4.1China .......................................................................................................... 172 11.4.1.1 China Minimal Residual Disease Testing Market (by Application) .................. 173 11.4.2India ............................................................................................................ 176 11.4.2.1 India Minimal Residual Disease Testing Market (by Application) .................... 177 11.4.3Japan .......................................................................................................... 178 11.4.3.1 Japan Minimal Residual Disease Testing Market (by Application) .................. 179 11.4.4South Korea ............................................................................................... 181 11.4.4.1 South Korea MRD Testing Market (by Application) ......................................... 183 11.4.5Australia ..................................................................................................... 185 11.4.5.1 Australia Minimal Residual Disease Testing Market (by Application) .............. 186 11.4.6Singapore ................................................................................................... 188 11.4.6.1 Singapore Minimal Residual Disease Testing Market (by Application) ........... 189 11.4.7Rest-of-APAC (RoAPAC) .......................................................................... 191 11.4.7.1 Rest-of-APAC Minimal Residual Disease Testing Market (by Application) ..... 192 11.5Latin America and Middle East ..................................................................... 194 11.5.1Brazil ........................................................................................................... 196 Global MRD Testing Market 11.5.1.1 Brazil Minimal Residual Disease Testing Market (by Application) ................... 197 11.5.2Mexico ........................................................................................................ 199 11.5.2.1 Mexico Minimal Residual Disease Testing Market (by Application) ................ 200 11.5.3Saudi Arabia .............................................................................................. 202 11.5.3.1 Saudi Arabia Minimal Residual Disease Testing Market (by Application) ....... 204 8 All rights reserved at BIS Research Inc.

  9. 11.5.4Rest-of-Latin America and Middle East ................................................... 205 11.5.4.1 Rest-of-Latin America and Middle East Minimal Residual Disease Testing Market (by Application) .................................................................................... 206 11.6Rest-of-the-World (RoW) ............................................................................... 209 11.6.1.1 Rest-of-the-World Minimal Residual Disease Testing Market (by Application) ...................................................................................................... 210 12.Company Profiles ..................................................................... 212 12.1Overview ......................................................................................................... 213 12.2ICON plc.......................................................................................................... 214 12.2.1Company Overview ................................................................................... 214 12.2.2Role of ICON plc in Global Minimal Residual Disease Testing Market .................................................................................................................... 214 12.2.3Key Customers of the Company .............................................................. 215 12.2.4Key Competitors of the Company ............................................................ 215 12.2.5Financials ................................................................................................... 215 12.2.6Analyst’s Perspective ............................................................................... 216 12.3ARUP Laboratories ........................................................................................ 218 12.3.1Company Overview ................................................................................... 218 12.3.2Role of ARUP Laboratories in Global Minimal Residual Disease Testing Market ........................................................................................... 218 12.3.3Key Customers of the Company .............................................................. 219 12.3.4Key Competitors of the Company ............................................................ 219 12.3.5Analyst’s Perspective ............................................................................... 220 12.4Cergentis B.V. ................................................................................................ 221 12.4.1Company Overview ................................................................................... 221 12.4.2Role of Cergentis B.V. in Global Minimal Residual Disease Testing Market ......................................................................................................... 221 Global MRD Testing Market 12.4.3Key Customers of the Company .............................................................. 222 12.4.4Key Competitors of the Company ............................................................ 222 12.4.5Analyst’s Perspective ............................................................................... 222 12.5Bio-Rad Laboratories, Inc. ............................................................................ 223 9 All rights reserved at BIS Research Inc.

  10. 12.5.1Company Overview ................................................................................... 223 12.5.2Role of Bio-Rad Laboratories, Inc. in Global Minimal Residual Disease Testing Market ............................................................................. 223 12.5.3Key Customers of the Company .............................................................. 224 12.5.4Key Competitors of the Company ............................................................ 224 12.5.5Financials ................................................................................................... 224 12.5.6Key Insights About Financial Health of the Company ........................... 226 12.5.7Analyst’s Perspective ............................................................................... 226 12.6Mission Bio, Inc. ............................................................................................ 228 12.6.1Company Overview ................................................................................... 228 12.6.2Role of Mission Bio, Inc. in Global Minimal Residual Disease Testing Market ........................................................................................... 228 12.6.3Key Customers of the Company .............................................................. 229 12.6.4Key Competitors of the Company ............................................................ 229 12.6.5Recent Developments ............................................................................... 229 12.6.6Analyst’s Perspective ............................................................................... 230 12.7Guardant Health ............................................................................................. 231 12.7.1Company Overview ................................................................................... 231 12.7.2Role of Guardant Health in Global Minimal Residual Disease Testing Market ........................................................................................... 231 12.7.3Key Customers of the Company .............................................................. 232 12.7.4Key Competitors of the Company ............................................................ 232 12.7.5Financials ................................................................................................... 232 12.7.6Key Insights About Financial Health of the Company ........................... 234 12.7.7Recent Developments ............................................................................... 234 12.7.8Analyst’s Perspective ............................................................................... 235 Global MRD Testing Market 12.8Invivoscribe, Inc. ............................................................................................ 236 12.8.1Company Overview ................................................................................... 236 12.8.2Role of Invivoscribe, Inc. in Global Minimal Residual Disease Testing Market ........................................................................................... 236 12.8.3Key Customers of the Company .............................................................. 237 10 All rights reserved at BIS Research Inc.

  11. 12.8.4Key Competitors of the Company ............................................................ 237 12.8.5Recent Developments ............................................................................... 237 12.8.6Analyst’s Perspective ............................................................................... 237 12.9Laboratory Corporation of America Holdings ............................................. 239 12.9.1Company Overview ................................................................................... 239 12.9.2Role of Laboratory Corporation of America Holdings in Global Minimal Residual Disease Testing Market .............................................. 239 12.9.3Key Customers of the Company .............................................................. 240 12.9.4Key Competitors of the Company ............................................................ 240 12.9.5Financials ................................................................................................... 240 12.9.6Analyst’s Perspective ............................................................................... 242 12.10Natera, Inc. ..................................................................................................... 243 12.10.1 Company Overview ............................................................................. 243 12.10.2 Role of Natera, Inc. in Global Minimal Residual Testing Market ..... 243 12.10.3 Key Customers of the Company ........................................................ 244 12.10.4 Key Competitors of the Company ..................................................... 244 12.10.5 Financials ............................................................................................ 244 12.10.6 Key Insights About Financial Health of the Company ..................... 246 12.10.7 Recent Developments ......................................................................... 247 12.10.8 Analyst’s Perspective ......................................................................... 247 12.11NeoGenomics Laboratories, Inc. .................................................................. 248 12.11.1 Company Overview ............................................................................. 248 12.11.2 Role of NeoGenomics Laboratories, Inc. in Global Minimal Residual Testing Market ........................................................................... 248 12.11.3 Key Customers of the Company ........................................................ 249 Global MRD Testing Market 12.11.4 Key Competitors of the Company ..................................................... 249 12.11.5 Financials ............................................................................................ 249 12.11.6 Key Insights About Financial Health of the Company ..................... 251 12.11.7 Recent Developments ......................................................................... 251 12.11.8 Analyst’s Perspective ......................................................................... 252 11 All rights reserved at BIS Research Inc.

  12. 12.12Opko Health, Inc. ........................................................................................... 253 12.12.1 Company Overview ............................................................................. 253 12.12.2 Role of Opko Health, Inc. in Global Minimal Residual Disease Testing Market ........................................................................................... 253 12.12.3 Key Customers of the Company ........................................................ 254 12.12.4 Key Competitors of the Company ..................................................... 254 12.12.5 Financials ............................................................................................ 255 12.12.6 Key Insights About Financial Health of the Company ..................... 256 12.12.7 Analyst’s Perspective ......................................................................... 256 12.13Quest Diagnostics Incorporated .................................................................. 258 12.13.1 Company Overview ............................................................................. 258 12.13.2 Role of Quest Diagnostics Incorporated in Global Minimal Residual Disease Testing Market ............................................................. 258 12.13.3 Key Customers of the Company ........................................................ 260 12.13.4 Key Competitors of the Company ..................................................... 260 12.13.5 Financials ............................................................................................ 260 12.13.6 Analyst’s Perspective ......................................................................... 261 12.14Sysmex Corporation ...................................................................................... 263 12.14.1 Company Overview ............................................................................. 263 12.14.2 Role of Sysmex Corporation in Global Minimal Residual Disease Testing Market ............................................................................. 263 12.14.3 Key Customers of the Company ........................................................ 264 12.14.4 Key Competitors of the Company ..................................................... 264 12.14.5 Financials ............................................................................................ 265 12.14.6 Key Insights About Financial Health of the Company ..................... 267 12.14.7 Analyst’s Perspective ......................................................................... 267 Global MRD Testing Market 12.15Adaptive Biotechnologies Corporation ....................................................... 269 12.15.1 Company Overview ............................................................................. 269 12.15.2 Role of Adaptive Biotechnologies Corporation in Global Minimal Residual Disease Testing Market .............................................. 269 12.15.3 Key Competitors of the Company ..................................................... 270 12 All rights reserved at BIS Research Inc.

  13. 12.15.4 Financials ............................................................................................ 270 12.15.5 Key Insights About Financial Health of the Company ..................... 271 12.15.6 Recent Developments ......................................................................... 272 12.15.7 Analyst’s Perspective ......................................................................... 272 12.16F. Hoffmann- La Roche Ltd ........................................................................... 274 12.16.1 Company Overview ............................................................................. 274 12.16.2 Role of F. Hoffmann-La Roche Ltd in Global Minimal Residual Disease Testing Market ............................................................................. 274 12.16.3 Key Customers of the Company ........................................................ 275 12.16.4 Key Competitors of the Company ..................................................... 275 12.16.5 Financials ............................................................................................ 275 12.16.6 Key Insights About Financial Health of the Company ..................... 277 12.16.7 Analyst’s Perspective ......................................................................... 278 Global MRD Testing Market 13 All rights reserved at BIS Research Inc.

  14. List of Figures Figure 1: Global Cancer Incidence, 2020 Figure 2: New Lymphoma Cases Expected in the U.S., 2022 Figure 3: Prevalence of Different Hematological Malignancies Across the U.S. (2018-2021) Figure 4: Global Minimal Residual Disease Testing Market, Impact Analysis Figure 5: Global MRD Testing Market (by Application), $Million, 2021 vs. 2027 Figure 6: Global MRD Testing Market (by Hematological Malignancy), $Million, 2021 vs. 2027 Figure 7: Global Minimal Residual Disease Testing Market (by Technology), $Million, 2021 vs. 2027 Figure 8: Global Minimal Residual Disease Testing Market (by End User), $Million, 2021 vs. 2027 Figure 9: Global Minimal Residual Disease Testing Market Snapshot Figure 10: Global MRD Testing Market Segments Figure 11: Global MRD Testing Market: Methodology Figure 12: Primary Research Methodology Figure 13: Bottom-Up Approach (Segment-Wise Analysis) Figure 14: Top-Down Approach (Segment-Wise Analysis) Figure 15: Global MRD Testing Market, $Million, 2021-2027 Figure 16: Global MRD Testing Market Potential, $Million, 2021-2027 Figure 17: Global Incidence and Mortality Rate for Individual Hematological Conditions, 2020 Figure 18: Global Incidence of Leukemia (by Region), 2020 Figure 19: Incidence of Hematological Malignancies in the U.S. (by Type), 2021 Figure 20: New Cases of Hematological Cancer in the U.S. (by Sex), 2021 Figure 21: Biomarker Evaluation and Evidentiary Considerations Figure 22: Regulatory Submissions for the Use of Minimal Residual Disease as a Biomarker Figure 23: Laboratory Methods for MRD Detection Figure 24: Classification of In-Vitro Diagnostics in India Figure 25: Methods to Achieve Coverage Figure 26: Supply Chain Analysis of Laboratory Developed Tests Figure 27: Supply Chain Analysis of In-Vitro Diagnostics Global MRD Testing Market Figure 28: Share of Key Developments and Strategies, January 2018-May 2022 Figure 29: Synergistic Activities Share (by Company), January 2018-May 2022 Figure 30: Product Approvals Share (by Company), January 2018-May 2022 Figure 31: Product Launches and Updates Share (by Company), January 2018-May 2022 Figure 32: Merger and Acquisition Activities Share (by Company), January 2018-May 2022 Figure 33: Business Expansion and Funding Activities Share (by Company), January 2018-May 2022 14 All rights reserved at BIS Research Inc.

  15. Figure 34: Market Share Analysis for Global MRD Testing Market, 2020 and 2021 Figure 35: Growth-Share Analysis for Global MRD Testing Market (by Company), 2019 Figure 36: Growth-Share Analysis for Global MRD Testing Market (by Technology), 2021-2027 Figure 37: Growth-Share Analysis for Global MRD Testing Market (by Application), 2021-2027 Figure 38: Growth-Share Analysis for Global MRD Testing Market (by End User), 2021-2027 Figure 39: Treatment Stage for MRD Testing Figure 40: Average Number of MRD Tests Per Patient Per Year Figure 41: Average Treatment Duration Figure 42: Perceived Importance of Key Drivers to Improve MRD Testing Adoption Figure 43: Agreement Level with Key Barriers to MRD Testing Adoption Figure 44: Reimbursement Scenario with respect to MRD Testing Figure 45: Price vs. Sensitivity vs. Turnaround Time Figure 46: Global Minimal Residual Disease Testing Market (by Technology), $Million, 2021-2027 Figure 47: Global Minimal Residual Disease Testing Market (Flow Cytometry), $Million, 2021-2027 Figure 48: Global Minimal Residual Disease Testing Market (Flow Cytometry), Thousand Units, 2021- 2027 Figure 49: Global Minimal Residual Disease Testing Market (PCR), $Million, 2021-2027 Figure 50: Global Minimal Residual Disease Testing Market (PCR), Thousand Units, 2021-2027 Figure 51: Global Minimal Residual Disease Testing Market (NGS), $Million, 2021-2027 Figure 52: Global Minimal Residual Disease Testing Market (by NGS), Thousand Units, 2021-2027 Figure 53: Global Minimal Residual Disease Testing Market (Other Technologies), $Million, 2021-2027 Figure 54: Global Minimal Residual Disease Testing Market (Other Technologies), Thousand Units, 2021-2027 Figure 55: Global MRD Testing Market (by Application) Figure 56: Global MRD Testing Market (by Application), 2021-2027 Figure 57: Global MRD Testing Market (by Hematological Malignancy), 2021 vs. 2027 Figure 58: Global Minimal Residual Disease Testing Market (Non-Hodgkin’s Lymphoma), $Million, 2021- 2027 Figure 59: Global Minimal Residual Disease Testing Market (by Non-Hodgkin’s Lymphoma Type), $Million, 2021 vs. 2027 Figure 60: Global NHL MRD Testing Market (by Age), $Million, 2021 vs. 2027 Global MRD Testing Market Figure 61: Global Minimal Residual Disease Testing Market (Multiple Myeloma), $Million, 2021-2027 Figure 62: Global MM MRD Testing Market (by Age), $Million, 2021 vs. 2027 Figure 63: Global Minimal Residual Disease Testing Market (Acute Lymphoblastic Leukemia), $Million, 2021-2027 Figure 64: Global ALL MRD Testing Market (by Age), $Million, 2021 vs. 2027 Figure 65: Global Minimal Residual Disease Testing Market (Chronic Lymphocytic Leukemia), $Million, 2021-2027 15 All rights reserved at BIS Research Inc.

  16. Figure 66: Global CLL MRD Testing Market (by Age), $Million, 2021 vs. 2027 Figure 67: Global Minimal Residual Disease Testing Market (Acute Myeloid Leukemia), $Million, 2021- 2027 Figure 68: Global AML MRD Testing Market (by Age), $Million, 2021 vs. 2027 Figure 69: Global Minimal Residual Disease Testing Market (Chronic Myeloid Leukemia), $Million, 2021- 2027 Figure 70: Global CML MRD Testing Market (by Age), $Million, 2021 vs. 2027 Figure 71: Global Minimal Residual Disease Testing Market (Hodgkin’s Lymphoma), $Million, 2021-2027 Figure 72: Global HL MRD Testing Market (by Age), $Million, 2021 vs. 2027 Figure 73: Global Minimal Residual Disease Testing Market (Other Leukemia), $Million, 2021-2027 Figure 74: Global Minimal Residual Disease Testing Market (by End User), $Million, 2021-2027 Figure 75: Global Minimal Residual Disease Testing Market (Hospitals and Specialty Clinics), $Million, 2021-2027 Figure 76: Global Minimal Residual Disease Testing Market (Hospitals and Specialty Clinics), Thousand Units, 2021-2027 Figure 77: Global Minimal Residual Disease Testing Market (Hospitals and Specialty Clinics) (by Technology), $Million, 2021 vs. 2027 Figure 78: Global Minimal Residual Disease Testing Market (Hospitals and Specialty Clinics) (by Technology), Thousand Units, 2021 vs. 2027 Figure 79: Global Minimal Residual Disease Testing Market (Diagnostic Laboratories), $Million, 2021- 2027 Figure 80: Global Minimal Residual Disease Testing Market (Diagnostic Laboratories), Thousand Units, 2021-2027 Figure 81: Global Minimal Residual Disease Testing Market (Diagnostic Laboratories) (by Technology), $Million, 2021 vs. 2027 Figure 82: Global Minimal Residual Disease Testing Market (Diagnostic Laboratories) (by Technology), Thousand Units, 2021 vs. 2027 Figure 83: Global Minimal Residual Disease Testing Market (Research Institutions), $Million, 2021-2027 Figure 84: Global Minimal Residual Disease Testing Market (Research Institutions), Thousand Units, 2021-2027 Figure 85: Global Minimal Residual Disease Testing Market (Research Institutions) (by Technology), $Million, 2021 vs. 2027 Figure 86: Global Minimal Residual Disease Testing Market (Research Institutions) (by Technology), Thousand Units, 2021 vs. 2027 Figure 87: Global Minimal Residual Disease Testing Market (Other End Users), $Million, 2021-2027 Global MRD Testing Market Figure 88: Global Minimal Residual Disease Testing Market (Other End Users), Thousand Units, 2021- 2027 Figure 89: Global Minimal Residual Disease Testing Market (Other End Users) (by Technology), $Million, 2021 vs.2027 Figure 90: Global Minimal Residual Disease Testing Market (Other End Users) (by Technology), Thousand Units, 2021 vs. 2027 Figure 91: Global Minimal Residual Disease Testing Market (by Region), $Million, 2021 and 2027 16 All rights reserved at BIS Research Inc.

  17. Figure 92: North America: Market Dynamics Figure 93: North America Minimal Residual Disease Testing Market, $Million, 2021-2027 Figure 94: North America Minimal Residual Disease Testing Market (by Country), $Million, 2021 vs. 2027 Figure 95: U.S. Minimal Residual Disease Testing Market, $Million, 2021-2027 Figure 96: U.S. Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027 Figure 97: U.S. Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021- 2027 Figure 98: Growth-Share Analysis for the U.S. Minimal Residual Disease Testing Market (by Application), 2021-2027 Figure 99: Canada Minimal Residual Disease Testing Market, $Million, 2021-2027 Figure 100: Canada Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027 Figure 101: Canada Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027 Figure 102: Growth-Share Analysis for Canada Minimal Residual Disease Testing Market (by Application), 2021-2027 Figure 103: Europe: Market Dynamics Figure 104: Europe Minimal Residual Disease Testing Market, $Million, 2021-2027 Figure 105: Europe Minimal Residual Disease Testing Market (by Country), $Million, 2021 vs. 2027 Figure 106: Germany Minimal Residual Disease Testing Market, $Million, 2021-2027 Figure 107: Germany Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027 Figure 108: Germany Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027 Figure 109: Growth-Share Analysis for Germany Minimal Residual Disease Testing Market (by Application), 2021-2027 Figure 110: Italy Minimal Residual Disease Testing Market, $Million, 2021-2027 Figure 111: Italy Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027 Figure 112: Italy Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021- 2027 Figure 113: Growth-Share Analysis for Italy Minimal Residual Disease Testing Market (by Application), 2021-2027 Figure 114: France Minimal Residual Disease Testing Market, $Million, 2021-2027 Figure 115: France Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027 Figure 116: France Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027 Global MRD Testing Market Figure 117: Growth-Share Analysis for France Minimal Residual Disease Testing Market (by Application), 2021-2027 Figure 118: U.K. Minimal Residual Disease Testing Market, $Million, 2021-2027 Figure 119: U.K. Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027 Figure 120: U.K. Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021- 2027 17 All rights reserved at BIS Research Inc.

  18. Figure 121: Growth-Share Analysis for the U.K. Minimal Residual Disease Testing Market (by Application), 2021-2027 Figure 122: Spain Minimal Residual Disease Testing Market, $Million, 2021-2027 Figure 123: Spain Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027 Figure 124: Spain Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027 Figure 125: Growth-Share Analysis for Spain Minimal Residual Disease Testing Market (by Application), 2021-2027 Figure 126: Rest-of-Europe Minimal Residual Disease Testing Market, $Million, 2021-2027 Figure 127: Rest-of-Europe Minimal Residual Disease Testing Market (by Application), $Million, 2021- 2027 Figure 128: Rest-of-Europe Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027 Figure 129: Growth-Share Analysis for Rest-of-Europe Minimal Residual Disease Testing Market (by Application), 2021-2027 Figure 130: Asia-Pacific: Market Dynamics Figure 131: Asia-Pacific Minimal Residual Disease Testing Market, $Million, 2021-2027 Figure 132: Asia-Pacific Minimal Residual Disease Testing Market (by Country), $Million, 2019 vs. 2025 Figure 133: China Minimal Residual Disease Testing Market, $Million, 2021-2027 Figure 134: China Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027 Figure 135: China Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027 Figure 136: Growth-Share Analysis for China Minimal Residual Disease Testing Market (by Application), 2021-2027 Figure 137: India Minimal Residual Disease Testing Market, $Million, 2021-2027 Figure 138: India Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027 Figure 139: India Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027 Figure 140: Growth-Share Analysis for India Minimal Residual Disease Testing Market (by Application), 2021-2027 Figure 141: Japan Minimal Residual Disease Testing Market, $Million, 2021-2027 Figure 142: Japan Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027 Figure 143: Japan Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027 Global MRD Testing Market Figure 144: Growth-Share Analysis for Japan Minimal Residual Disease Testing Market (by Application), 2021-2027 Figure 145: South Korea Minimal Residual Disease Testing Market, $Million, 2021-2027 Figure 146: South Korea Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027 Figure 147: South Korea Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027 Figure 148: Growth Share Analysis for South Korea MRD Testing Market (by Application), 2021-2027 18 All rights reserved at BIS Research Inc.

  19. Figure 149: Australia Minimal Residual Disease Testing Market, $Million, 2021-2027 Figure 150: Australia Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027 Figure 151: Australia Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027 Figure 152: Growth-Share Analysis for Australia Minimal Residual Disease Testing Market (by Application), 2021-2027 Figure 153: Singapore Minimal Residual Disease Testing Market, $Million, 2021-2027 Figure 154: Singapore Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027 Figure 155: Singapore Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027 Figure 156: Growth-Share Analysis for Singapore Minimal Residual Disease Testing Market (by Application), 2021-2027 Figure 157: Rest-of-APAC Minimal Residual Disease Testing Market, $Million, 2021-2027 Figure 158: Rest-of-APAC Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027 Figure 159: Rest-of-APAC Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027 Figure 160: Growth-Share Analysis for Rest-of-APAC Minimal Residual Disease Testing Market (by Application), 2021-2027 Figure 161: Latin America: Market Dynamics Figure 162: Latin America and Middle East Minimal Residual Disease Testing Market, $Million, 2021-2027 Figure 163: Latin America and Middle East Minimal Residual Disease Testing Market (by Country), $Million, 2021 vs. 2027 Figure 164: Brazil Minimal Residual Disease Testing Market, $Million, 2021-2027 Figure 165: Brazil Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027 Figure 166: Brazil Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027 Figure 167: Growth-Share Analysis for Brazil Minimal Residual Disease Testing Market (by Application), 2021-2027 Figure 168: Mexico Minimal Residual Disease Testing Market, $Million, 2021-2027 Figure 169: Mexico Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027 Figure 170: Mexico Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027 Figure 171: Growth-Share Analysis for Mexico Minimal Residual Disease Testing Market (by Application), 2021-2027 Global MRD Testing Market Figure 172: Saudi Arabia Minimal Residual Disease Testing Market, $Million, 2021-2027 Figure 173: Saudi Arabia Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027 Figure 174: Saudi Arabia Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027 Figure 175: Growth-Share Analysis for Saudi Arabia Minimal Residual Disease Testing Market (by Application), 2021-2027 19 All rights reserved at BIS Research Inc.

  20. Figure 176: Rest-of-Latin America and Middle East Minimal Residual Disease Testing Market, $Million, 2021-2027 Figure 177: Rest-of-Latin America and Middle East Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027 Figure 178: Rest-of-Latin America and Middle East Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027 Figure 179: Growth-Share Analysis for Rest-of-Latin America and Middle East Minimal Residual Disease Testing Market (by Application), 2021-2027 Figure 180: Rest-of-the-World Minimal Residual Disease Testing Market, $Million, 2021-2027 Figure 181: Rest-of-the-World Minimal Residual Disease Testing Market (by Application), $Million, 2021- 2027 Figure 182: Rest-of-the-World Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027 Figure 183: Growth-Share Analysis for Rest-of-the-World Minimal Residual Disease Testing Market (by Application), 2021-2027 Figure 184: Total Number of Companies Profiled Figure 185: ICON plc: Overall Product Portfolio Figure 186: ICON plc: Overall Financials, $Million, 2019-2021 Figure 187: ICON plc: Revenue (by Region), $Million, 2019-2021 Figure 188: ARUP Laboratories: Product Portfolio Figure 189: Cergentis B.V.: Product Portfolio Figure 190: Bio-Rad Laboratories, Inc.: Product Portfolio Figure 191: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2019-2021 Figure 192: Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2019-2021 Figure 193: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2019-2021 Figure 194: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021 Figure 195: Mission Bio, Inc.: Product Portfolio Figure 196: Guardant Health: Portfolio Figure 197: Guardant Health: Overall Financials, $Million, 2019-2021 Figure 198: Guardant Health: Revenue (by Segment), $Million, 2019-2021 Figure 199: Guardant Health: Revenue (by Region), $Million, 2019-2021 Figure 200: Guardant Health: R&D Expenditure, $Million, 2019-2021 Global MRD Testing Market Figure 201: Invivoscribe, Inc.: Product Portfolio Figure 202: Laboratory Corporation of America Holdings: Product Portfolio Figure 203: Laboratory Corporation of America Holdings: Overall Financials, $Million, 2019-2021 Figure 204: Laboratory Corporation of America Holdings: Revenue (by Segment), $Million, 2019-2021 Figure 205: Laboratory Corporation of America Holdings: Revenue (by Region), $Million, 2019-2021 Figure 206: Natera, Inc.: Portfolio 20 All rights reserved at BIS Research Inc.

  21. Figure 207: Natera, Inc.: Overall Financials, $Million, 2019-2021 Figure 208: Natera, Inc.: Revenue (by Segment), $Million, 2019-2021 Figure 209: Natera, Inc.: Sales (by Region), $Million, 2019-2021 Figure 210: Natera, Inc.: R&D Expenditure, $Million, 2019-2021 Figure 211: NeoGenomics Laboratories, Inc.: Portfolio Figure 212: NeoGenomics Laboratories, Inc.: Overall Financials, $Million, 2019-2021 Figure 213: NeoGenomics Laboratories, Inc.: Revenue (by Segment), $Million, 2019-2021 Figure 214: NeoGenomics Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021 Figure 215: Opko Health: Portfolio Figure 216: Opko Health, Inc.: Overall Financials, $Million, 2019-2021 Figure 217: Opko Health, Inc.: Revenue (by Segment), $Million, 2019-2021 Figure 218: Opko Health, Inc.: R&D Expenditure, $Million, 2019-2021 Figure 219: Quest Diagnostics Incorporated: Product Portfolio Figure 220: Quest Diagnostics Incorporated: Overall Financials, $Million, 2019-2021 Figure 221: Quest Diagnostics Incorporated: Revenue (by Segment), $Million, 2019-2021 Figure 222: Sysmex Corporation: Product Portfolio Figure 223: Sysmex Corporation: Overall Financials, $Million, 2019-2021 Figure 224: Sysmex Corporation: Revenue (by Business Segment), $Million, 2019-2021 Figure 225: Sysmex Corporation: Revenue (by Region), $Million, 2019-2021 Figure 226: Sysmex Corporation R&D Expenditure, $Million, 2019-2021 Figure 227: Adaptive Biotechnologies Corporation: Product Portfolio Figure 228: Adaptive Biotechnologies Corporation: Overall Financials, $Million, 2019-2021 Figure 229: Adaptive Biotechnologies Corporation: Revenue (by Business Segment), $Million, 2019-2021 Figure 230: Adaptive Biotechnologies Corporation R&D Expenditure, $Million, 2019-2021 Figure 231: F. Hoffmann-La Roche Ltd: Portfolio Figure 232: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2019-2021 Figure 233: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2019-2021 Figure 234: F. Hoffmann-La Roche Ltd: Revenue (by Region), $Million, 2019-2021 Figure 235: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2019-2021 Global MRD Testing Market 21 All rights reserved at BIS Research Inc.

  22. List of Tables Table 1: Likert Scale Table 2: Impact Analysis of Market Drivers Table 3: Impact Analysis of Market Restraints Table 4: Current Research Grants and Funding in the U.S., 2021 Table 5: MRD False Positive and Negative (by Relapse State) Table 6: List of Approved MRD Tests by Major Players Table 7: List of Launched MRD Tests (by Major Players) Table 8: Key Notable Developments Table 9: Key Notable Developments Table 10:Comparison of FDA and EMA Draft Guidance Table 11:Registration Criteria for IVD Medical Devices as per CFDA Table 12:Key Coverage Providers for Hematologic Malignancies Testing Table 13:Key Products Offered Based on Flow Cytometry Table 14:Key Products Offered Based on PCR Table 15:Key Products Offered Based on NGS Global MRD Testing Market 22 All rights reserved at BIS Research Inc.

  23. BIS Research Offerings: We are on a mission to harness the potential of disruptive technologies to make businesses thrive in today’s digital age. We have the vision to be a leading and preferred knowledge partner for corporates and institutions worldwide and assist them with market intelligence in the area of emerging technologies, advisories, and other innovative solutions. Know More Know More Know More Global MRD Testing Market Know More 23 All rights reserved at BIS Research Inc.

  24. Disclaimer BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth. This document and its contents are confidential and may not be further distributed, published or reproduced, in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce Information in legal proceedings. Market reports are based on expectations, estimates and projections as of the date such information is available. Any recommendation contained in this report may not be suitable for all investors or businesses. The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to market fluctuations and business, economic and competitive uncertainties, and contingencies For more details regarding permission, please contact us: Email: sales@bisresearch.com Tel: +1 510 404 8135 Global MRD Testing Market 24 All rights reserved at BIS Research Inc.

  25. BIS RESEARCH INC. 39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686 E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135 Global MRD Testing Market Global Delivery Center Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway, Sector 126, Noida, U.P., 201303, India Tel: +91 120 4261540 / 4261544 www.bisresearch.com 25 All rights reserved at BIS Research Inc.

More Related